IL160706A0 - Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use - Google Patents

Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use

Info

Publication number
IL160706A0
IL160706A0 IL16070602A IL16070602A IL160706A0 IL 160706 A0 IL160706 A0 IL 160706A0 IL 16070602 A IL16070602 A IL 16070602A IL 16070602 A IL16070602 A IL 16070602A IL 160706 A0 IL160706 A0 IL 160706A0
Authority
IL
Israel
Prior art keywords
glp
receptor agonists
pharmacological methods
peptides acting
peptides
Prior art date
Application number
IL16070602A
Other languages
English (en)
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of IL160706A0 publication Critical patent/IL160706A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16070602A 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use IL160706A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32773001P 2001-10-05 2001-10-05
PCT/US2002/031693 WO2003040309A2 (en) 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Publications (1)

Publication Number Publication Date
IL160706A0 true IL160706A0 (en) 2004-08-31

Family

ID=23277790

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16070602A IL160706A0 (en) 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use

Country Status (27)

Country Link
US (6) US7399745B2 (de)
EP (1) EP1436330A4 (de)
JP (1) JP2005508639A (de)
KR (1) KR20050034580A (de)
CN (1) CN1326876C (de)
AR (1) AR036711A1 (de)
BR (1) BR0213132A (de)
CA (1) CA2462462A1 (de)
CO (1) CO5570710A2 (de)
DO (1) DOP2002000475A (de)
EC (2) ECSP024346A (de)
HN (1) HN2002000282A (de)
HR (1) HRP20040327A2 (de)
HU (1) HUP0401797A2 (de)
IL (1) IL160706A0 (de)
MA (1) MA26228A1 (de)
MX (1) MXPA04002140A (de)
MY (1) MY138267A (de)
NO (1) NO20041792L (de)
NZ (1) NZ532685A (de)
PE (1) PE20030850A1 (de)
PL (1) PL368760A1 (de)
RU (1) RU2334761C2 (de)
SG (2) SG158736A1 (de)
UY (1) UY27469A1 (de)
WO (1) WO2003040309A2 (de)
ZA (1) ZA200403322B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
EP1605897B1 (de) 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelen-glycol-link-glp-1-verbindungen
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
MXPA06006745A (es) 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2570133B1 (de) * 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagonanaloga mit physiologischer Löslichkeit und Stabilität
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
RU2477286C2 (ru) * 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
AU2008216265B2 (en) * 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008098693A2 (en) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Convergent synthesis of glp-1
US8980830B2 (en) * 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009125424A2 (en) * 2007-12-11 2009-10-15 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
AU2009210570B2 (en) * 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
CL2009000586A1 (es) 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
DK2300035T3 (en) * 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (de) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Coagonisten des glucagon/glp-1 rezeptors
WO2009155257A1 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2460527A1 (de) 2010-01-21 2012-06-06 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
EP2528618A4 (de) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Glucagon-antagonisten- und gip-agonisten-konjugate sowie zusammensetzungen zur behandlung von stoffwechselerkrankungen und adipositas
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
CA2828761C (en) 2011-03-04 2017-04-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
EP2548570A1 (de) 2011-07-19 2013-01-23 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP3098235A4 (de) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Langwirkendes insulin und verwendung davon
US10189884B2 (en) 2014-04-28 2019-01-29 The Trustees Of The University Of Pennsylvania Thioamide-modified peptides and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
US9796759B2 (en) 2014-07-21 2017-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
WO2020115113A1 (en) 2018-12-04 2020-06-11 Københavns Universitet Dual agonist glp-1 and neurotensin fusion peptide
US12591761B2 (en) 2018-12-05 2026-03-31 Shape Security, Inc. Execution of trained neural networks using a database system
US11934931B2 (en) * 2018-12-17 2024-03-19 Shape Security, Inc. Decision tree training using a database system
WO2020254479A1 (en) * 2019-06-18 2020-12-24 Fresenius Kabi Ipsum S.R.L. Process for the manufacture of glucagon
US12406209B1 (en) 2019-06-28 2025-09-02 Shape Security, Inc. Decision tree training using a database system
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
WO2024233999A2 (en) 2023-05-11 2024-11-14 University Hospitals Cleveland Medical Center Anxiolytic therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
CA2100874A1 (en) * 1991-01-17 1992-07-18 Robert A. Smith Methods for detecting glucagon antagonists
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
US5782802A (en) * 1996-03-22 1998-07-21 Vitajet Corporation Multiple use needle-less hypodermic injection device for individual users
US6232310B1 (en) * 1999-03-12 2001-05-15 Novo Nordisk A/S Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Also Published As

Publication number Publication date
US20060003417A1 (en) 2006-01-05
EP1436330A2 (de) 2004-07-14
US20050153890A1 (en) 2005-07-14
PL368760A1 (en) 2005-04-04
RU2334761C2 (ru) 2008-09-27
NO20041792L (no) 2004-07-02
CN1326876C (zh) 2007-07-18
ECSP024346A (es) 2003-05-26
US7488716B2 (en) 2009-02-10
US7399745B2 (en) 2008-07-15
AR036711A1 (es) 2004-09-29
NZ532685A (en) 2006-02-24
MXPA04002140A (es) 2005-03-07
ZA200403322B (en) 2005-05-03
ECSP045094A (es) 2004-06-28
US20060003418A1 (en) 2006-01-05
BR0213132A (pt) 2004-10-19
DOP2002000475A (es) 2003-06-30
SG149693A1 (en) 2009-02-27
CA2462462A1 (en) 2003-05-15
MY138267A (en) 2009-05-29
RU2004114243A (ru) 2005-05-10
CO5570710A2 (es) 2005-10-31
EP1436330A4 (de) 2006-01-18
UY27469A1 (es) 2003-04-30
US20050288248A1 (en) 2005-12-29
WO2003040309A2 (en) 2003-05-15
SG158736A1 (en) 2010-02-26
US20060003934A1 (en) 2006-01-05
KR20050034580A (ko) 2005-04-14
US7494978B2 (en) 2009-02-24
HK1073117A1 (zh) 2005-09-23
PE20030850A1 (es) 2003-10-31
HN2002000282A (es) 2002-12-12
US7488714B2 (en) 2009-02-10
CN1564828A (zh) 2005-01-12
HUP0401797A2 (en) 2006-08-28
HRP20040327A2 (en) 2007-11-30
MA26228A1 (fr) 2004-07-01
US7488715B2 (en) 2009-02-10
JP2005508639A (ja) 2005-04-07
WO2003040309A3 (en) 2003-12-18
US20060003419A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
IL160706A0 (en) Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
EP1883419A4 (de) Glucagon-like peptid-1 (glp-1)-rezeptoragonisten und deren pharmakologische verwendungsverfahren
AU7524601A (en) T cell receptor fusions and conjugates and methods of use thereof
AU2002366384A8 (en) Insulin and igf-1 receptor agonists and antagonists
IL192111A0 (en) Human receptor proteins; related reagents and methods
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL160512A0 (en) Virus coat protein/receptor chimeras and methods of use
AU4134101A (en) Hormone receptor functional entities and methods of their use
HUP0203371A3 (en) Adenosine receptor antagonists and methods of making and using the same
IL176223A0 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
PL373052A1 (en) Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof
AU2002351175A8 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
AU6503900A (en) Chemokine receptor antagonists and methods of use therefor
AU9275001A (en) Notch receptor agonists and uses
AU6389900A (en) Chemokine receptor antagonists and methods of use therefor
IL161669A0 (en) Chemokine receptor antagonists and methods of use thereof
ZA200205485B (en) Human and parasite orphan receptor proteins.
EP1423402A4 (de) Neue polypeptidanaloga und -fusionsprodukte und deren verwendung
AU2003300122A1 (en) Agonists and antagonists of the human odorant receptor or17-4 and uses thereof
EP1210102A4 (de) Tgf-alpha polypeptide, funktionelle frangmente und methoden zu deren verwendung
EP1539955A4 (de) Polynukleotide g-protein-gekoppelter rezeptoren und verfahren zur verwendung davon
AU2001285707A1 (en) Peptides of the alpha1-adrenergic receptor and their use for psoriasis
IL149266A0 (en) Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension